HbA1c News and Research

RSS

EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured

From EKF Diagnostics 23 Feb 2015

Study: Definitive indicator of diabetes control deceptively high in African-American children

A new study confirms the findings of two earlier LSU Health New Orleans studies that the definitive indicator of diabetes control, the HbA1c, is deceptively high in African-American children.

19 Feb 2015

Large majority of coronary patients fail to meet lifestyle, risk factor targets

The large majority of coronary patients in Europe are failing to achieve their lifestyle, risk factor and therapeutic targets as set out in the latest prevention guidelines.

17 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Study: About one-third of teens, young adults face social barriers to diabetes management

Managing type 1 diabetes is a never-ending task that requires multiple blood glucose tests, carbohydrate calculations and insulin injections or infusions. This constant effort to control the disease is daunting at any age - and it's especially challenging for teens and young adults.

2 Feb 2015

Postprandial glucagon linked to glycaemic control in Type 1 diabetes

Research shows that postprandial glucagon levels increase over time in children with newly diagnosed Type 1 diabetes, and are associated with worsening glycaemic control, suggesting an adjunctive treatment approach.

30 Jan 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Closed-loop artificial pancreas system improves diabetes management in adolescents

Research shows that the use of an artificial pancreas system helps to compensate for omission and underestimation of insulin boluses in adolescents with Type 1 diabetes.

1 Dec 2014

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

21 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control.

29 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests.

5 Sep 2014

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

4 Sep 2014

Diet reduces inflammatory markers in ‘real world’ Type 2 diabetes

Encouraging patients newly diagnosed with Type 2 diabetes to diet or to diet and increase their physical activity reduces markers of inflammation and their cardiovascular risk compared with usual care, real-world study findings show.

15 Aug 2014

Almonds can help reduce inflammation in people with poorly controlled diabetes

Evidence continues to mount supporting the role of almonds and other tree nuts as part of an overall dietary pattern that is beneficial for those with type 2 diabetes. Three new studies suggest a relationship between regular consumption of tree nuts, such as almonds, and improvement in various markers of health in type 2 diabetes.

12 Aug 2014

Inadequate management common in young-onset Type 2 diabetes

Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort.

8 Aug 2014

New, promising approach combines metformin and SGLT2 inhibitors to treat diabetes

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012.

4 Aug 2014